🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

The ESMO Handbook on Nutrition and Cancer (Second edition) is out now. Excellent publication and free for ESMO - Eur. Oncology Members. Please download oncologypro.esmo.org/education-libr… OncoAlert BTOG Christie Library

Stephen V Liu, MD It is a very important news for French pts with RET fusion advanced NSCLC as France did not accept selpercatib nor praseltinib access even conditional Haute Autorité de santé Ministère de la Santé et de l'Accès aux soins Aurélien Rousseau it is time to have to selpercatinib access. alk ros1 france cancer poumon Mon Réseau Cancer du Poumon IFCT lung

Pilar Garrido Lizza Hendriks d.planchard @Dingemans_AnneM Enriqueta Felip ESMO - Eur. Oncology Beaumont RCSI Cancer Centre - charocampelo: neoadj + adj IO - me! Jarushka Naidoo: mesothelioma, thymoma Lisbon in November, will be fun ESMO - Eur. Oncology #LCSM #IrishLungCancerAlliance #IrishLungCancerCommunity RCSI Research and Innovation

Michael Duruisseaux And access to selpercatinib for the French RET+ NSCLC patients for whom there is no drug available in early access. @HAS refused this access in absence of CT comparative trials by contrast to other UE countries. It is time to urgently change this inequality Ministère de la Santé et de l'Accès aux soins

We publish an update on the multidisciplinary management of TKI-induced diarrhea, a problem that affects the patient's quality of life, even in grade 1 due to long-term treatment Instituto Nacional de Cancerología UFOT INCan Jenny Turcott Andres F. Cardona journals.sagepub.com/doi/epub/10.11…

Un milliard de morts ☠️ sur la planète depuis l’invention de la cigarette. C’est sûr que vous pouvez être “fiers” du chemin parcouru ! 😡

Press release: two phase III studies of lenvatinib + pembrolizumab in NSCLC negative. LEAP-006 was 1L platinum + pemetrexed + pembrolizumab +/- lenvatinib did not improve OS. LEAP-008 was 2L pembro + lenvatinib vs docetaxel (post-IO). Await full data. merck.com/news/merck-and…

#ESMO23 Poster 1373P with outcomes from TRUST-II of talectrectinib in #ROS1 NSCLC. 1L RR 92% with 80% intracranial response rate, medians not reached. Dizziness does not seem to be a major issue with this agent, perhaps TrkB selection important?

🎯ROS1. Impressive results with taletrectinib. 92% RR (👍👍) and 57% following previous ROS1 tki (👍). #ESMO23 OncoAlert Maurice Perol

Fantastic presentation by Zosia Piotrowska - balanced, thoughtful and poised discussion of MARIPOSA and MARIPOSA-2 ESMO Open #ESMO23 ➡️ Highlights that chronic toxicities, even low grade can affect QOL, cc Jill Feldman ➡️ Patient oriented approach will be KEY! EGFR Resisters

Thank you for the invitation IASLC ! Promising results for #BRAF-mutant lung cancer, yet much to be done re. - Therapy sequence (ICI vs targeted therapy) - Resistance to therapy We work on some of these challenges in the #BOLEROConsortium #LCAM23 #LCSM CRCL Centre Leon Berard

C’est maintenant l’heure de la « lecture critique d’articles » : merci à Florian Guisier et Aurélie Swalduz! #17eme_Réunion_Clinico_Pathologique_en_Oncologie_Thoracique GFPC

GFPC 08–2015 ENERGY trial published today in The Lancet Respiratory Medicine. Important study led by Lena Herve in frail pts (≥70yo or PS 2) evaluating Nivo-Ipi vs SOC for aNSCLC. So proud to co-author this paper. Thanks GFPC for trusting our team CHU de Rennes 👉shorturl.at/acyR8

I am pleased to share that I am running for the Board of Directors in the ASCO Election. Learn more about me and the 12 other remarkable candidates at asco.org/election, and then make your voice heard!

Proud to share the result of a great team effort! Huge thanks to my colleagues at Centre Leon Berard : Maurice Perol Sandra Ortiz-Cuaran , all our co-investigators, and Inivata for their invaluable support in making this academic project a success 🙏🏽 Now in JTO & JTO CRR 📚

A date to watch

Taletrectinib in ROS1+ Non–Small Cell Lung Cancer: TRUST I and II TKI-naïve ORR➡️88.8% Cranial ORR➡️76.5% mPFS➡️45.6 mo‼️ TKI-pretreated ORR➡️55.8% Cranial ORR➡️65.6% mPFS➡️9.7 mo ascopubs.org/doi/10.1200/JC…

Comparison of the Efficacy and Side Effects of ROS1 Inhibitors👇

🚨🔥OncoAlert Hot Off The Press U.S. FDA approves #Taletrectinib for locally advanced or metastatic #ROS1+ non-small cell #LungCancer. Approval based on #TRUST I & II Trials. ✅#ORR: 85-90% for treatment-naive pts. 52-62% or TKI-pretreated pts. 👇🏻 fda.gov/drugs/resource…

Now that Taletrectinib is approved by @usfda for metastatic NSCLC Check out the comparison of data for three ROS-1 inhibitors, entrectinib , repotrectinib and Taletrectinib. Useful for quick summary of data for all 3 . Rami Manochakian MD, FASCO Cancer Education OncoAlert Oncology Brothers Kate Sears